RUPINDER KAUR: Open Payments
NPI 1740213982 · GREENSBORO, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,731 in 127 payments from 12 companies in 2025. Trend: 2023 $2,586 · 2024 $1,860 · 2025 $1,731
Food & beverage: $1,722Education: $9
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 31 | $356 |
| Neurocrine BioSciences, Inc. | 20 | $228 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $220 |
| Alkermes, Inc. | 22 | $216 |
| Janssen Pharmaceuticals, Inc | 10 | $193 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $146 |
| Otsuka America Pharmaceutical, Inc. | 9 | $137 |
| Axsome Therapeutics, Inc. | 5 | $84 |
| Vanda Pharmaceuticals Inc. | 3 | $61 |
| Teva Pharmaceuticals USA, Inc. | 2 | $37 |
Products named: VRAYLAR, INGREZZA, CAPLYTA, SPRAVATO, TRINTELLIX, REXULTI, LYBALVI, ARISTADA.
Industry payments across NC — which companies pay providers there.
